Last reviewed · How we verify
Actonel®
At a glance
| Generic name | Actonel® |
|---|---|
| Also known as | Risedronate, Risedronate Sodium |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women (PHASE4)
- Denosumab Safety Assessment in Multiple Observational Databases
- A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) (PHASE3)
- CCEF in the Treatment of Acute VFFs: Randomized Controlled Trial (NA)
- Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients (NA)
- Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
- Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture (NA)
- Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Actonel® CI brief — competitive landscape report
- Actonel® updates RSS · CI watch RSS
- Amgen portfolio CI